| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Trastuzumab emtansine |
| Brand | Kadcyla® |
| Indication | For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination. |
| Assessment Process | |
| Rapid review commissioned | 25/09/2013 |
| Rapid review completed | 24/10/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 05/02/2014 |
| NCPE assessment completed | 30/06/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended. |
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
December 2015
The HSE has approved reimbursement following confidential price negotiations.
